The Financial Times reported on the challenges of bringing new antibiotics to market and the growing political will to remedy the problem.
The article highlighted the efforts of the AMR Action Fund and featured Board Chair Bill Burns. “You’ve got a broken business model,” Burns said. “Venture capital has very little interest in supporting biotech companies developing antibiotics.” Read the full article here
